These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32948433)

  • 41. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
    Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
    J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The visibility of prostate cancer concerning underlying histopathological variances: A single-center multiparametric magnetic resonance imaging study.
    Arslan A; Alis D; Tuna MB; Sağlıcan Y; Kural AR; Karaarslan E
    Eur J Radiol; 2021 Aug; 141():109791. PubMed ID: 34062471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists.
    Berney DM; Algaba F; Camparo P; Compérat E; Griffiths D; Kristiansen G; Lopez-Beltran A; Montironi R; Varma M; Egevad L
    Histopathology; 2014 Feb; 64(3):405-11. PubMed ID: 24102975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.
    Iczkowski KA; Egevad L; Ma J; Harding-Jackson N; Algaba F; Billis A; Camparo P; Cheng L; Clouston D; Comperat EM; Datta MW; Evans AG; Griffiths DF; Guo CC; Hailemariam S; Huang W; Humphrey PA; Jiang Z; Kahane H; Kristiansen G; La Rosa FG; Lopez-Beltran A; MacLennan GT; Magi-Galluzzi C; Merrimen J; Montironi R; Osunkoya AO; Picken MM; Rao N; Shah RB; Shanks JH; Shen SS; Tawfik OW; True LD; Van der Kwast T; Varma M; Wheeler TM; Zynger DL; Sahr N; Bostwick DG
    Ann Diagn Pathol; 2014 Dec; 18(6):333-42. PubMed ID: 25263387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma.
    Montironi R; Cimadamore A; Gasparrini S; Mazzucchelli R; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):685-693. PubMed ID: 29699428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome of Gleason 3 + 5 = 8 Prostate Cancer Diagnosed on Needle Biopsy: Prognostic Comparison with Gleason 4 + 4 = 8.
    Harding-Jackson N; Kryvenko ON; Whittington EE; Eastwood DC; Tjionas GA; Jorda M; Iczkowski KA
    J Urol; 2016 Oct; 196(4):1076-81. PubMed ID: 27265220
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome.
    van der Slot MA; Hollemans E; den Bakker MA; Hoedemaeker R; Kliffen M; Budel LM; Goemaere NNT; van Leenders GJLH
    Virchows Arch; 2021 Feb; 478(2):249-256. PubMed ID: 32815034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of Prostate HistoScanning as a Method for Targeted Biopsy in Routine Practice.
    Glybochko PV; Alyaev YG; Amosov AV; Krupinov GE; Nir D; Winkler M; Ganzha TM
    Eur Urol Focus; 2019 Mar; 5(2):179-185. PubMed ID: 28753891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
    Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey.
    Bukavina L; Tilburt JC; Konety B; Shah ND; Gross CP; Yu JB; Schumacher F; Kutikov A; Smaldone MC; Kim SP
    Eur Urol Focus; 2020 Mar; 6(2):273-279. PubMed ID: 30219709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists.
    McClelland S; Sandler KA; Degnin C; Chen Y; Mitin T
    Clin Genitourin Cancer; 2018 Apr; 16(2):e323-e325. PubMed ID: 29174501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evolution of prostate cancer histopathology.
    Compérat E
    Curr Opin Urol; 2019 Nov; 29(6):587-592. PubMed ID: 31453865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The 2019 International Society of Urological Pathology Consensus Conference on Prostate Cancer Grading.
    van Leenders GJLH; van der Kwast TH; Iczkowski KA
    Eur Urol; 2021 Jun; 79(6):707-709. PubMed ID: 32847702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolution, controversies and the future of prostate cancer grading.
    Egevad L; Delahunt B; Yaxley J; Samaratunga H
    Pathol Int; 2019 Feb; 69(2):55-66. PubMed ID: 30694570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?
    Drobish JN; Bevill MD; Tracy CR; Sexton SM; Rajput M; Metz CM; Gellhaus PT
    Urol Oncol; 2021 Apr; 39(4):235.e1-235.e4. PubMed ID: 33451935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
    Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
    Buisset J; Norris JM; Puech P; Leroy X; Ramdane N; Drumez E; Villers A; Olivier J
    J Urol; 2021 Mar; 205(3):725-731. PubMed ID: 33080153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contemporary prostate biopsy reporting: insights from a survey of clinicians' use of pathology data.
    Varma M; Narahari K; Mason M; Oxley JD; Berney DM
    J Clin Pathol; 2018 Oct; 71(10):874-878. PubMed ID: 29720406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.